-
Lead Identification & Optimization
-
Lead Identification & Optimization
How many hits (binders) should be further analyzed? How to select candidates of interest? Which par
...
-
Multi/Bi Specifics
Combination strategies - combining immune checkpoint inhibitors, cytokines, and immune cell-engaging
...
-
Multi/Bi Specifics
The opportunity in oncology and autoimmune disease The challenge to develop Bi/Multi Specifics Antib
...
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Drinks-Canape Reception
-
Lead Identification & Optimization
-
Lead Identification & Optimization
Functional screening vs binding assays. Engineering antibodies to enhance Fc-region-mediated effecto
...
-
Antibody Drug Conjugates
Payload to drug ratio optimization to achieve optimal results. Engineering ADC payloads with optimiz
...
-
Multi/Bi Specifics
Successful bispecific antibody production requires the correct assembly of multiple peptide chains t
...
-
Antibody Drug Conjugates
The SpyCatcher SpyTag reaction is a fast and specific way to covalently link two proteins and has pr
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
This session will explore effective strategies for accelerating lead selection from a diverse panel
...
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Afternoon Refreshments
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
1-2-1 Meetings / Networking Break
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
1-2-1 Meetings / Networking Break
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Antibody fragments like Fab, ScFv, and VHH are emerging stars in antibody drug development, utilized
...
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Networking Lunch
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
1-2-1 Meetings / Networking Break
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
1-2-1 Meetings / Networking Break
-
Multi/Bi Specifics
Need for costimulation through CD28, CD137 or cytokines. Tailoring costimulatory signals to tumor in
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
Design tools, eg. computational modeling and high-throughput screening to identify bi-specific produ
...
-
Antibody Drug Conjugates
Target selection: Can we identify cancer-specific targets so critical to tumor cell function that ca
...
-
Formats & Scaffolds
Combination vs. Bi-Specific Approaches: combining multiple mAbs to design multi-functional or bi-spe
...
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Off-target binding is a significant hurdle in the development of antibody-based therapies, contribut
...
-
-
Antibody Drug Conjugates
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
Registration
)
How many hits (binders) should be further analyzed? How to select candidates of interest? Which par ...)
The opportunity in oncology and autoimmune disease The challenge to develop Bi/Multi Specifics Antib ...)
Successful bispecific antibody production requires the correct assembly of multiple peptide chains t ...)
This session will explore effective strategies for accelerating lead selection from a diverse panel ...)
Off-target binding is a significant hurdle in the development of antibody-based therapies, contribut ...
)
)
)
)
)
)
)
)
)
)